These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 11707844)

  • 1. Weekly x 4 induction therapy with the anti-CD20 antibody rituximab: effect on circulating t(14;18)(+) follicular lymphoma cells.
    Pichert G; Schmitz SF; Hess U; Cerny T; Cogliatti SB; Betticher D; Stupp R; Schmitter D; Stahel RA; Ghielmini M
    Clin Lymphoma; 2001 Mar; 1(4):293-7. PubMed ID: 11707844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
    Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
    Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
    Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
    Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
    J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response.
    Foran JM; Gupta RK; Cunningham D; Popescu RA; Goldstone AH; Sweetenham JW; Pettengell R; Johnson PW; Bessell E; Hancock B; Summers K; Hughes J; Rohatiner AZ; Lister TA
    Br J Haematol; 2000 Apr; 109(1):81-8. PubMed ID: 10848785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients.
    Hirt C; Schüler F; Kiefer T; Schwenke C; Haas A; Niederwieser D; Neser S; Assmann M; Srock S; Rohrberg R; Dachselt K; Leithäuser M; Rabkin CS; Herold M; Dölken G
    Br J Haematol; 2008 May; 141(5):631-40. PubMed ID: 18422779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.
    Feuring-Buske M; Kneba M; Unterhalt M; Engert A; Gramatzki M; Hiller E; Trümper L; Brugger W; Ostermann H; Atzpodien J; Hallek M; Aulitzky E; Hiddemann W
    Ann Hematol; 2000 Sep; 79(9):493-500. PubMed ID: 11043420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma.
    Mandigers CM; Meijerink JP; Mensink EJ; Tönnissen EL; Hebeda KM; Bogman MJ; Raemaekers JM;
    Blood; 2001 Aug; 98(4):940-4. PubMed ID: 11493436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The significance of molecular response of follicular lymphoma to central lymphatic irradiation as measured by polymerase chain reaction for t(14;18)(q32;q21).
    Ha CS; Tucker SL; Lee MS; McLaughlin P; Cabanillas F; Cox JD
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):727-32. PubMed ID: 11172955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?
    Schmitt C; Grundt A; Buchholtz C; Scheuer L; Benner A; Hensel M; Ho AD; Leo E
    Leuk Res; 2006 Dec; 30(12):1563-8. PubMed ID: 16530831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy.
    Czuczman MS; Grillo-López AJ; McLaughlin P; White CA; Saleh M; Gordon L; LoBuglio AF; Rosenberg J; Alkuzweny B; Maloney D
    Ann Oncol; 2001 Jan; 12(1):109-14. PubMed ID: 11249036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follicular lymphoma: 2012 update on diagnosis and management.
    Freedman A
    Am J Hematol; 2012 Oct; 87(10):988-95. PubMed ID: 23001911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LightCycler-based quantitative real-time PCR monitoring of patients with follicular lymphoma receiving rituximab in combination with conventional or high-dose cytotoxic chemotherapy.
    Martin S; Fischer C; Free M; Kurreck B; Stockinger H; Fenk R; Arnold C; Kliszewski S; Meckenstock G; Haas R; Kronenwett R
    Eur J Haematol; 2005 Apr; 74(4):282-92. PubMed ID: 15777339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.
    Ghielmini M; Schmitz SF; Cogliatti SB; Pichert G; Hummerjohann J; Waltzer U; Fey MF; Betticher DC; Martinelli G; Peccatori F; Hess U; Zucca E; Stupp R; Kovacsovics T; Helg C; Lohri A; Bargetzi M; Vorobiof D; Cerny T
    Blood; 2004 Jun; 103(12):4416-23. PubMed ID: 14976046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
    Piro LD; White CA; Grillo-López AJ; Janakiraman N; Saven A; Beck TM; Varns C; Shuey S; Czuczman M; Lynch JW; Kolitz JE; Jain V
    Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De novo acute B cell leukemia/lymphoma with t(14;18).
    Stamatoullas A; Buchonnet G; Lepretre S; Lenain P; Lenormand B; Duval C; Callat MP; Gaulard P; Bastard C; Tilly H
    Leukemia; 2000 Nov; 14(11):1960-6. PubMed ID: 11069032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two cases.
    Kennedy GA; Blum R; McCormack C; Prince HM
    Australas J Dermatol; 2004 Feb; 45(1):34-7. PubMed ID: 14961906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follicular lymphoma: 2014 update on diagnosis and management.
    Freedman A
    Am J Hematol; 2014 Apr; 89(4):429-36. PubMed ID: 24687887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged molecular and clinical remission after treatment of a patient with follicular lymphoma with rituximab.
    Buckstein RJ; Rimrie K; Pennell N; Spaner D; Hewitt K; Berinstein NL
    Leuk Lymphoma; 2001 Apr; 41(3-4):451-5. PubMed ID: 11378562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.
    Colombat P; Salles G; Brousse N; Eftekhari P; Soubeyran P; Delwail V; Deconinck E; Haïoun C; Foussard C; Sebban C; Stamatoullas A; Milpied N; Boué F; Taillan B; Lederlin P; Najman A; Thièblemont C; Montestruc F; Mathieu-Boué A; Benzohra A; Solal-Céligny P
    Blood; 2001 Jan; 97(1):101-6. PubMed ID: 11133748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.